AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alkermes Expects Record $1B Proprietary Sales in 2025 Amid Orexin Pipeline Advancements
ByAinvest
Tuesday, Jul 29, 2025 2:50 pm ET1min read
Alkermes anticipates record proprietary product sales of over $1 billion for 2025, driven by progress in its orexin pipeline. The company's CEO described the quarter as "very successful" with strong commercial and financial performance, and stated that Alkermes is on track to deliver on its key objectives for the year. The company is also now sustainably profitable and debt-free.
DUBLIN, July 2, 2025 — Alkermes plc (Nasdaq: ALKS) reported its financial results for the second quarter of 2025, showcasing robust performance across its proprietary products. The company generated revenues of $390.7 million, up from $399.1 million in the same period last year, and reported GAAP net income of $87.1 million, an increase from $94.7 million in the second quarter of 2024 [1].Key financial highlights include:
- Revenues: Total revenues increased to $390.7 million, with proprietary net sales reaching $307.2 million.
- Profitability: GAAP net income from continuing operations was $87.1 million, while EBITDA from continuing operations stood at $101.6 million.
- Product Performance: Revenues for VIVITROL®, ARISTADA®, and LYBALVI® grew by 9%, 18%, and 18% respectively, compared to the second quarter of 2024.
CEO Richard Pops noted that the quarter was "very successful," highlighting strong commercial and financial performance. He also reiterated the company's 2025 financial expectations, including record proprietary product sales of over $1 billion, driven by progress in its orexin pipeline [1].
Alkermes is also now sustainably profitable and debt-free, with cash, cash equivalents, and total investments reaching $1.05 billion as of June 30, 2025, up from $916.2 million at March 31, 2025 [1].
The company will present detailed Vibrance-1 results at the upcoming World Sleep Congress and topline results from Vibrance-2 in patients with narcolepsy type 2 this fall. These studies underscore the potential of orexin 2 receptor agonists to transform the treatment of narcolepsy [1].
References:
[1] https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-second-quarter-2025-financial-results
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet